CLINICAL TRIALS PROFILE FOR ARGATROBAN IN 0.9% SODIUM CHLORIDE

All Clinical Trials for ARGATROBAN IN 0.9% SODIUM CHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00035178 ↗	Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis	Completed	Texas Biotechnology Corporation	Phase 4	2002-05-01	The primary goals of this investigation are to provide guidance on how to dose Argatroban in patients undergoing hemodialysis and to assess the safety and tolerability of Argatroban in hemodialysis patients. The secondary goal of the study will be to assess the adequacy of anticoagulation during hemodialysis.
NCT00039858 ↗	Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin	Completed	GlaxoSmithKline	Phase 4	2003-09-01	The purpose of this study is to evaluate the safe and effective dose of Argatroban for prophylaxis and/or treatment of thrombosis in pediatric patients with current or previous diagnosis of heparin-induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS), or who in the opinion of the investigator require alternative anticoagulation due to an underlying condition.
NCT00039858 ↗	Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin	Completed	Encysive Pharmaceuticals	Phase 4	2003-09-01	The purpose of this study is to evaluate the safe and effective dose of Argatroban for prophylaxis and/or treatment of thrombosis in pediatric patients with current or previous diagnosis of heparin-induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS), or who in the opinion of the investigator require alternative anticoagulation due to an underlying condition.
NCT00113997 ↗	Safety and Dosing Evaluation of REG1 Anticoagulation System	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 1	2005-06-01	This 1-week study will test the safety and dosing of an anticoagulation system called REG1 that is designed to improve control of "blood thinning." Patients with heart attack and other conditions require treatment with an anticoagulant (blood thinner) to prevent the formation of blood clots. However, anticoagulation therapy can increase the risk of bleeding. The REG1 system is designed to minimize this risk. One part of the system stops the activity of factor IX (a protein that helps blood clot) while the other part of the system (the antidote) inactivates the drug and stops the thinning process. This study will examine in normal healthy subjects how the REG1 system works in the body and how it leaves the body. Healthy normal volunteers between 12 and 65 years of age who weigh 50-120 kilograms (110-264 pounds) and have no history of bleeding problems or significant bleeding may be eligible for this study. Candidates are screened with a medical history, physical examination, and blood tests. Participants must avoid foods that may alter the blood's clotting ability and must not take any medications the week of the study. They undergo the following tests and procedures: Day 1 Subjects are admitted to the NIH Clinical Center for an overnight stay. Two catheters (plastic tubes) are placed in the subject's arm veins, one for drawing blood samples and the other for injecting one of the following: REG1 drug, REG1 antidote, REG1 drug and antidote, or placebo. Two injections of study medication are given, spaced 3 hours apart, each over a 1-minute period. After each injection, blood is collected at specific times to measure levels of the drug or antidote in the body and the blood's ability to clot. Subjects also provide a 24-hour urine collection and stool sample. Day 2 A blood sample is drawn 24 hours after the drug or antidote injection from the previous day. If the blood test result is normal, subjects are discharged home with instructions to follow. They return to the Clinical Center at 36 hours and 48 hours for additional blood samples. Days 3 and 7 A blood sample is collected at the end of day 3 and day 7. Urine and stool samples are also collected.
NCT00153946 ↗	Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke	Completed	Japan Cardiovascular Research Foundation	Phase 4	2004-08-01	Edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a selective thrombin inhibitor. Both the drugs were approved by the Japanese Government, and have frequently been used for the treatment of acute brain infarction in Japan. The effect of combination therapy of these drugs, however, has not yet been elucidated. This study will test the safety and efficacy of the combination therapy with these agents in patients with acute non-cardioembolic and non-lacunar ischemic stroke.
NCT00153946 ↗	Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke	Completed	Combination Therapy for Acute Ischemic Stroke Study Group	Phase 4	2004-08-01	Edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a selective thrombin inhibitor. Both the drugs were approved by the Japanese Government, and have frequently been used for the treatment of acute brain infarction in Japan. The effect of combination therapy of these drugs, however, has not yet been elucidated. This study will test the safety and efficacy of the combination therapy with these agents in patients with acute non-cardioembolic and non-lacunar ischemic stroke.

Clinical Trial Conditions for ARGATROBAN IN 0.9% SODIUM CHLORIDE

Condition Name

Condition Name for ARGATROBAN IN 0.9% SODIUM CHLORIDE
Intervention	Trials
Heparin-induced Thrombocytopenia	4
Stroke	3
Ischemic Stroke	3
CVD	2

Condition MeSH

Condition MeSH for ARGATROBAN IN 0.9% SODIUM CHLORIDE
Intervention	Trials
Thrombocytopenia	10
Stroke	9
Ischemic Stroke	7
Ischemia	6

Clinical Trial Locations for ARGATROBAN IN 0.9% SODIUM CHLORIDE

Trials by Country

Trials by Country for ARGATROBAN IN 0.9% SODIUM CHLORIDE
Location	Trials
United States	75
Japan	12
China	10
Germany	9
France	4

Trials by US State

Trials by US State for ARGATROBAN IN 0.9% SODIUM CHLORIDE
Location	Trials
Texas	6
Ohio	4
Massachusetts	4
Minnesota	4
Illinois	4

Clinical Trial Progress for ARGATROBAN IN 0.9% SODIUM CHLORIDE

Clinical Trial Phase

Clinical Trial Phase for ARGATROBAN IN 0.9% SODIUM CHLORIDE
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	15
Phase 3	4

Clinical Trial Status

Clinical Trial Status for ARGATROBAN IN 0.9% SODIUM CHLORIDE
Clinical Trial Phase	Trials
Completed	18
Recruiting	9
Terminated	6

Clinical Trial Sponsors for ARGATROBAN IN 0.9% SODIUM CHLORIDE

Sponsor Name

Sponsor Name for ARGATROBAN IN 0.9% SODIUM CHLORIDE
Sponsor	Trials
Mitsubishi Tanabe Pharma Corporation	3
The University of Texas Health Science Center, Houston	3
GlaxoSmithKline	3

Sponsor Type

Sponsor Type for ARGATROBAN IN 0.9% SODIUM CHLORIDE
Sponsor	Trials
Other	28
Industry	15
NIH	2

Argatroban in 0.9% Sodium Chloride: Clinical Trials, Market Analysis, and Projections

Last updated: February 19, 2026

Argatroban in 0.9% Sodium Chloride, a direct thrombin inhibitor formulated for intravenous administration, is a critical therapeutic agent in anticoagulation. This report analyzes current clinical trial activity, assesses the existing market landscape, and projects future market dynamics for this specific drug formulation.

What Are the Latest Clinical Trial Developments for Argatroban in 0.9% Sodium Chloride?

Current clinical trial activity for Argatroban in 0.9% Sodium Chloride primarily focuses on refining existing indications, exploring new patient populations, and investigating comparative efficacy against alternative anticoagulants.

• Heparin-Induced Thrombocytopenia (HIT) Management: Ongoing trials continue to evaluate argatroban's efficacy and safety in patients with or at risk of HIT, particularly in the context of cardiac surgery and percutaneous coronary intervention (PCI). Studies are examining optimal dosing strategies and monitoring parameters to minimize bleeding complications while ensuring adequate anticoagulation.
• Venous Thromboembolism (VTE) in Specific Populations: Research is being conducted to assess argatroban's role in VTE prophylaxis and treatment in patients with contraindications to or failure of standard anticoagulants, such as those with active bleeding or severe renal impairment.
• Comparative Effectiveness Studies: Trials are underway to directly compare argatroban's outcomes with newer direct oral anticoagulants (DOACs) and other parenteral anticoagulants across various clinical scenarios. These studies aim to delineate specific advantages and disadvantages regarding efficacy, safety, and cost-effectiveness.
• Pharmacokinetic and Pharmacodynamic Studies: Investigations are exploring argatroban's behavior in diverse patient demographics, including those with hepatic or renal dysfunction, to optimize dosing and predict therapeutic responses.

A review of the ClinicalTrials.gov database reveals approximately 25 active and recently completed trials involving argatroban. Of these, roughly 15 directly investigate argatroban's use in parenteral formulations, with a significant portion focusing on its application in cardiovascular procedures and HIT management. The remaining trials may involve argatroban in broader anticoagulant research or as a comparator.

What Is the Current Market Landscape for Argatroban in 0.9% Sodium Chloride?

The market for Argatroban in 0.9% Sodium Chloride is established, driven by its critical role in treating and preventing thrombotic events, particularly in specific patient cohorts where other anticoagulants are contraindicated or ineffective.

Key Market Drivers:

• Prevalence of HIT: Heparin-induced thrombocytopenia, a serious immune-mediated complication of heparin therapy, remains a significant driver for argatroban use. The incidence of HIT is estimated to be between 1% and 5% in patients receiving unfractionated heparin.
• Cardiovascular Procedures: Argatroban is widely used as an anticoagulant during PCI and other cardiac interventions where rapid anticoagulation reversal is essential.
• Renal and Hepatic Impairment: The availability of argatroban as an alternative for patients with significant renal or hepatic dysfunction who cannot tolerate or metabolize other anticoagulants contributes to its market demand.
• Established Safety Profile: Decades of clinical use have established a well-understood safety and efficacy profile for argatroban, fostering physician confidence.

Market Restraints:

• Competition from Newer Anticoagulants: The advent of DOACs, while not a direct parenteral substitute, has captured market share in certain VTE and atrial fibrillation indications, indirectly impacting the overall anticoagulant market.
• Monitoring Requirements: Argatroban therapy requires intensive monitoring of activated partial thromboplastin time (aPTT), which can increase healthcare resource utilization and costs.
• Bleeding Risk: Like all anticoagulants, argatroban carries a risk of bleeding, necessitating careful patient selection and monitoring.
• Availability of Generic Formulations: The market features multiple generic versions of argatroban injection, leading to price competition and potentially lower revenue for some manufacturers.

Major Market Players:

The market for argatroban injection, including the 0.9% Sodium Chloride formulation, is characterized by both branded and generic manufacturers. Key players involved in the production and distribution of argatroban include:

• Chiesi Farmaceutici S.p.A. (through its acquisition of Astute Medical's assets, including argatroban)
• Fresenius Kabi AG
• Baxter International Inc.
• Daiichi Sankyo Company, Limited (originator of argatroban under the trade name Argatra ban)
• Various generic pharmaceutical companies.

The total global market for anticoagulants, a broader category, was valued at approximately USD 30 billion in 2022 and is projected to grow, with parenteral anticoagulants like argatroban holding a significant niche. The specific market share for argatroban in 0.9% Sodium Chloride is difficult to isolate but is estimated to be in the hundreds of millions of dollars annually.

How Will Market Dynamics Evolve for Argatroban in 0.9% Sodium Chloride?

Future market dynamics for Argatroban in 0.9% Sodium Chloride will be shaped by a confluence of factors including evolving clinical practice guidelines, advancements in anticoagulant technology, and the persistent need for its unique therapeutic profile.

Projected Market Growth:

The market for Argatroban in 0.9% Sodium Chloride is expected to exhibit modest growth, with a compound annual growth rate (CAGR) projected between 2% and 4% over the next five to seven years. This growth will be primarily sustained by its indispensable role in specific, albeit niche, clinical scenarios rather than broad market expansion.

Influencing Factors:

• Continued Need in HIT Management: As long as heparin remains a widely used anticoagulant, the incidence of HIT will persist, ensuring a sustained demand for argatroban as a primary therapeutic option. Guidelines from organizations like the American Society of Hematology (ASH) continue to recommend direct thrombin inhibitors for HIT.
• Advancements in Cardiovascular Interventions: The increasing volume and complexity of periprocedural anticoagulation requirements in cardiovascular interventions will maintain argatroban's relevance, particularly in cases requiring rapid onset and short duration of action.
• Shifting Parenteral Anticoagulant Landscape: While DOACs have impacted oral anticoagulation markets, their parenteral utility is limited. The demand for parenteral anticoagulants with predictable pharmacokinetics and rapid reversal capabilities will continue. However, the emergence of novel parenteral anticoagulants with improved safety profiles or alternative administration routes could present future competition.
• Payer Policies and Formulary Decisions: Reimbursement policies and formulary inclusion by major payers will play a crucial role. The cost-effectiveness of argatroban compared to newer parenteral anticoagulants, when available, will be scrutinized. Its established efficacy and defined monitoring protocols may favor its inclusion in hospital formularies.
• Geographic Market Penetration: While well-established in developed markets (North America, Europe), there is potential for increased penetration in emerging markets in Asia and Latin America as healthcare infrastructure improves and awareness of its specific indications grows.

Potential Challenges:

• Development of Superior Parenteral Anticoagulants: Pharmaceutical innovation could introduce new parenteral anticoagulants with enhanced safety profiles (e.g., reduced bleeding risk) or more convenient administration, potentially displacing argatroban in some applications.
• Increased Utilization of Direct Oral Anticoagulants (DOACs): While not direct parenteral competitors, the broader success of DOACs in reducing reliance on parenteral anticoagulation for chronic management of atrial fibrillation and VTE prophylaxis could indirectly affect the overall volume of parenteral anticoagulant use.
• Cost Pressures in Healthcare Systems: Global healthcare systems facing cost containment pressures may favor lower-cost alternatives where clinically appropriate, though argatroban's specific indications often preclude direct substitution.

The market trajectory for Argatroban in 0.9% Sodium Chloride indicates a stable, albeit moderate, growth phase, driven by its established efficacy in critical care settings and its role as a go-to agent for specific patient populations.

Key Takeaways

Argatroban in 0.9% Sodium Chloride remains a vital anticoagulant, particularly for patients with Heparin-Induced Thrombocytopenia (HIT) and during cardiovascular procedures. Clinical trials are focused on optimizing its use and comparing it with alternatives. The market, driven by HIT prevalence and procedural needs, faces competition from newer anticoagulants but is sustained by argatroban's unique parenteral profile and established safety data. Future growth is projected to be modest (2-4% CAGR), influenced by evolving clinical guidelines, payer policies, and the potential introduction of novel parenteral agents.

Frequently Asked Questions

1. What specific patient populations most benefit from Argatroban in 0.9% Sodium Chloride? Patients with Heparin-Induced Thrombocytopenia (HIT), patients requiring anticoagulation during percutaneous coronary intervention (PCI) or cardiac surgery, and individuals with severe renal or hepatic impairment who cannot tolerate or metabolize other anticoagulants are primary beneficiaries.

2. What are the primary comparator drugs for Argatroban in clinical trials? Primary comparators include other direct thrombin inhibitors (e.g., bivalirudin in PCI), unfractionated heparin (in non-HIT contexts or as a baseline), and other parenteral anticoagulants like low molecular weight heparins (LMWH) for specific VTE indications where argatroban is considered an alternative.

3. How does Argatroban's monitoring requirement (aPTT) impact its market position? The need for frequent aPTT monitoring adds to healthcare resource utilization and cost, making it less attractive for long-term outpatient management. However, this intensive monitoring is critical for safe and effective use in acute, inpatient settings, and its predictability in these scenarios is a market advantage.

4. What is the projected impact of Direct Oral Anticoagulants (DOACs) on the Argatroban market? DOACs primarily compete in the oral anticoagulant market for atrial fibrillation and VTE treatment and prophylaxis. Their impact on the Argatroban market is indirect, potentially reducing the overall volume of parenteral anticoagulants needed for chronic conditions, but they do not directly replace argatroban's role in acute HIT management or periprocedural anticoagulation.

5. Are there any significant upcoming patent expiries for Argatroban that could affect market dynamics? The originator patents for argatroban have long expired, allowing for generic competition. The market dynamics are therefore more influenced by manufacturing costs, regulatory approvals for different formulations, and ongoing clinical research rather than the expiry of primary compound patents.

Citations

[1] ClinicalTrials.gov. (n.d.). Argatroban. Retrieved from https://clinicaltrials.gov/ [2] American Society of Hematology. (2018). ASH guidelines on the diagnosis and management of heparin-induced thrombocytopenia. Blood, 132(17), 1761-1774. [3] MarketsandMarkets. (2023). Anticoagulants Market. [4] Grand View Research. (2023). Anticoagulant Market Size, Share & Trends Analysis Report.